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Abstract
 
The maturation of dendritic cells (DCs) allows these antigen-presenting cells to initiate immu-
nity. We pursued this concept in situ by studying the adjuvant action of 
 
 
 
-galactosylceramide
(
 
 
 
GalCer) in mice. A single i.v. injection of glycolipid induced the full maturation of splenic
DCs, beginning within 4 h. Maturation was manifest by marked increases in costimulator and
major histocompatibility complex class II expression, interferon (IFN)-
 
 
 
 production, and stim-
ulation of the mixed leukocyte reaction. These changes were not induced directly by 
 
 
 
GalCer
but required natural killer T (NKT) cells acting independently of the MyD88 adaptor protein.
To establish that DC maturation was responsible for the adjuvant role of 
 
 
 
GalCer, mice were
given 
 
 
 
GalCer together with soluble or cell-associated ovalbumin antigen. Th1 type CD4
 
 
 
and CD8
 
 
 
 T cell responses developed, and the mice became resistant to challenge with ovalbu-
min-expressing tumor. DCs from mice given ovalbumin plus adjuvant, but not the non-DCs,
stimulated ovalbumin-specific proliferative responses and importantly, induced antigen-spe-
cific, IFN-
 
 
 
 producing, CD4
 
 
 
 and CD8
 
 
 
 T cells upon transfer into naive animals. In the latter
instance, immune priming did not require further exposure to ovalbumin, 
 
 
 
GalCer, NKT, or
NK cells. Therefore a single dose of 
 
 
 
GalCer i.v. rapidly stimulates the full maturation of DCs
in situ, and this accounts for the induction of combined Th1 CD4
 
 
 
 and CD8
 
 
 
 T cell immu-
nity to a coadministered protein.
Key words:
 
 
 
-galactosylceramide • dendritic cell maturation • dendritic cells • exogenous 
pathway • T cell–mediated immunity
 
Introduction
 
It is important to identify new immune adjuvants to im-
prove the efficacy of vaccines against human tumors and
many infectious diseases such as tuberculosis, malaria, and
AIDS (1, 2). Available adjuvants, like alum and CFA, are
suboptimal in that alum can polarize the immune response
toward a Th2 type (3), while CFA can induce suppressive
macrophages (4) and cytokines (5).
Adjuvants potentially could act at many sites in the im-
mune response, e.g., directly on T cells (6) or on DCs (7).
DCs charged with antigens ex vivo are able to induce adap-
tive immunity upon injection into rodents and humans,
both CD4
 
 
 
 and CD8
 
 
 
 T cells. To do so, the injected DCs
need to be stimulated ex vivo to undergo an intricate dif-
ferentiation process termed maturation (8–12). In this
way, the injected antigen-bearing mature DCs serve as
“nature’s adjuvants.”
It would be desirable to identify adjuvants that would
harness the DC system directly in situ for the purpose of
controlling immunity. For example DCs are specialized to
present nonreplicating antigens on MHC class I products to
CD8
 
 
 
 T cells (for reviews, see references 13 and 14). DC
stimulation through toll-like receptors (15–17) and by
CD4
 
 
 
 T cells (18, 19) induces some features of DC matu-
ration in vivo
 
.
 
 In recent experiments, antigen also has been
targeted selectively to DCs in vivo together with an agonis-
tic anti-CD40 antibody to stimulate differentiation of DCs
and many other cell types. The combination of antigen tar-
geting to DCs combined with anti-CD40 leads to strong
Th1 CD4
 
 
 
 (20) and CD8
 
 
 
 (21, 22) T cell responses. The
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presentation of antigen leading to the induction of effector
T cells and memory is consistent with the full maturation
of DCs. While these approaches draw a correlation be-
tween DC maturation and the development of immunity,
it remains to be shown directly that antigen-capturing ma-
turing DCs in vivo are the mediators of immunization.
The synthetic glycolipid 
 
 
 
-galactosylceramide (
 
 
 
Gal-
Cer)
 
*
 
 enhances resistance to tumors (23–26) and several in-
tracellular infections (27–29). The glycolipid is presented to
NKT cells by CD1d molecules particularly on DCs (30).
Presentation by DCs leads to a rapid innate response and
then a more prolonged production of IFN-
 
 
 
 by the NKT
cells (31). It is also known that 
 
 
 
GalCer acts as an adjuvant
for CD8
 
 
 
 T cell–dependent protection against malaria in-
fection, when the glycolipid is administered together with
an irradiated sporozoite vaccine (32). These results are sur-
prising because 
 
 
 
GalCer has been used to reduce T cell–
mediated autoimmune diseases (33–38). The mechanism of
adjuvant action of 
 
 
 
GalCer is therefore of interest to deci-
pher, especially in the contexts of adjuvant action and DC
maturation. Also this glycolipid appears to lack major tox-
icity in humans and may be useful in the design of vaccines
and therapies (39). In this paper, we describe the capacity
of 
 
 
 
GalCer to act as a stimulus for the full maturation DCs
in mice, and we show with an adoptive transfer approach
that the mature DCs exclusively mediate the glycolipid’s
role as an adjuvant to help prime antigen-specific, Th1
CD4
 
 
 
 and CD8
 
 
 
 T cell–mediated immunity.
 
Materials and Methods
 
Mice.
 
Pathogen-free C57BL/6 (B6), and TAP
 
 
 
/
 
 
 
 female
mice at 6–7 wk were purchased from The Jackson Laboratory.
We were generously provided with OT-I and OT-II TCR trans-
genic mice by Dr. F. Carbone (University of Melbourne,
Parkville, Victoria, Australia), MyD88
 
 
 
/
 
 
 
 mice by Dr. S. Akira
(Osaka University, Osaka, Japan), and J
 
 
 
281
 
 
 
/
 
 
 
 mice by Dr. M.
Taniguchi (Chiba University, Chiba, Japan). Mice were main-
tained under specific pathogen-free conditions in the animal facil-
ity of the Rockefeller University. All experiments were done in
compliance with relevant laws and institutional guidelines.
 
Reagents.
 
 
 
GalCer (2S, 3S, 4R-1-O(a-galactopyranosyl)-
2(N-hexacosanoylamino)-1,3,4-octadecanetriol) was provided
by the Pharmaceutical Research Laboratory, Kirin Brewery
(Gunma, Japan) and diluted in PBS. OVA protein was pur-
chased from Seikagaku Corp. LPS was purchased from Sigma-
Aldrich, and CpG-DNA from TriLink BioTechnologies. The
following mAbs were purchased from BD Biosciences: FITC-
conjugated anti-CD8
 
 
 
 or PE-conjugated anti-CD11c, CD44,
CD62L, biotinylated-isotype control, anti-CD40, CD80, CD86,
I-A
 
b
 
, and V
 
 
 
2. Biotinylated mAbs were detected with streptavi-
din-APC. The following mAbs were purified from hybridoma
culture supernatants: anti-CD4, anti-CD8, anti-DEC205, and
agonistic FGK45.5 anti-CD40 Ab. Rabbit polyclonal anti-asialo
GM1, rabbit-IgG, and rat-IgG were purchased from Wako Pure
Chemical USA Industries and Jackson ImmunoResearch Labo-
ratories, respectively.
 
Flow Cytometry.
 
Cells were preincubated with 2.4G2 culture
supernatant to block Fc
 
 
 
 receptors, then washed and incubated
with the indicated mAb conjugates for 30 min. Cells were
washed and analyzed on a FACSCalibur™ flow cytometer (Bec-
ton Dickinson). For intracellular cytokine staining by FACS
 
®
 
,
5 
 
 
 
 10
 
6
 
 spleen cells were cultured in 24-well plates for 6 or 8 h in
the absence or presence of 1 
 
 
 
M OVA
 
257–264
 
 peptide (for CD8
 
 
 
T cells), or 2 
 
 
 
M OVA
 
323–339
 
 peptide (for CD4
 
 
 
 T cells) with
GolgiPlug (BD Biosciences) to accumulate cytokines intracellu-
larly. The cells were incubated for 15 min at 4
 
 
 
C with the 2.4G2
anti-Fc
 
 
 
R mAb to block nonspecific staining. Then we stained
cells with anti-CD4 or anti-CD8-FITC, or V
 
 
 
2-biotin and
streptavidin-APC, for 20 min at room temperature. The cells
were permeabilized using Cytofix/Cytoperm Plus™ (BD Bio-
sciences) and stained with PE-conjugated anti-IFN-
 
 
 
 (XMG1.2)
or anti-IL-4 (11B11) mAb for 15 min at room temperature. Flow
cytometry used a FACSCalibur™ instrument and CELLQuest™
software (BD Biosciences) or FlowJo (Tree Star).
 
DC Preparation from Spleen.
 
DCs were isolated from spleens
using prior methods (40). In brief, splenocytes were released by
homogenization followed by treatment with collagenase (collage-
nase D; Roche Diagnostics Corporation). A DC-enriched cell
population was obtained as a low-density cell fraction using gra-
dients. Collagenase-treated spleens were suspended in a dense
BSA solution, overlaid with 1 ml of PBS, and centrifuged for 30
min. We separated low density CD11c
 
 
 
 and CD11c
 
 
 
 fractions
using anti-CD11c coated magnetic beads (Miltenyi Biotech). To
isolate DC subsets on the basis of CD8
 
 
 
 expression (41), we first
depleted the low density spleen cells of CD5
 
 
 
 and CD19
 
 
 
 lym-
phocytes (T and B cells) with magnetic beads. From the lympho-
cyte-negative fraction, we selected CD8
 
 
 
 and then CD11c
 
 
 
 cells
(CD8
 
 
 
 DCs). No difference in viability was observed between
CD8
 
 
 
 
 
 and CD8
 
 
 
 
 
 DCs.
 
Cytokine Production by DCs.
 
After mice were given 
 
 
 
GalCer,
LPS, or PBS i.v., CD11c
 
 
 
 and CD11c
 
 
 
 cells were isolated with
anti-CD11c magnetic beads and cultured at 2 
 
 
 
 10
 
5
 
 or 3 
 
 
 
 10
 
5
 
cells/well for 48–72 h in the absence or presence of FGK45.5
anti-CD40 mAb (10 
 
 
 
g/ml). The titers of IFN-
 
 
 
, IL-4, IL-10,
IL-12p40, and IL-18 in the culture supernatants were determined
by OptEIA™ Kit (BD Biosciences), and IL-12p70 was deter-
mined by Quantikine ELISA kit (R&D Systems).
 
Stimulation of the Mixed Leukocyte Reaction by DCs.
 
Spleen
DCs were isolated using anti-CD11c magnetic beads 8 h after
administration of 
 
 
 
GalCer, LPS, or PBS. Graded numbers of
spleen DCs from C57BL/6 mice were irradiated and cultured
with 2 
 
 
 
 10
 
5
 
 allogeneic BALB/C or syngeneic T cells, isolated
using T cell enrichment columns (R&D Systems), in a 96-well
flat-bottom plate for 88 h. During the final 16 h, 
 
3
 
H-thymidine
(1 
 
 
 
Ci/well) was added. In some experiments, DCs were fixed
with 0.75% paraformaldehyde (Electron Microscopy Science) for
30 min on ice.
 
DC Presentation of OVA.
 
To assess the role of 
 
 
 
GalCer as an
adjuvant for a T cell–mediated immune response, we used OVA
as antigen in part because antigen presentation can be readily
monitored using CD4
 
 
 
 and CD8
 
 
 
 OVA-specific TCR trans-
genic T cells. OVA was administered to mice i.v. either as a solu-
ble protein (where 5 mg was required) or in association with dy-
ing osmotically shocked, syngeneic, TAP
 
 
 
/
 
 
 
 splenocytes (where
only 1 
 
 
 
g was associated with the injected cells; the dying cells
efficiently target to DCs in spleen, accounting for the high effi-
ciency of presentation as described [42]). Briefly, spleen cells were
incubated with hypertonic medium at 37
 
 
 
C in the presence or
absence of 10 mg/ml OVA for 10 min, and further incubated
 
*
 
Abbreviations used in this paper:
 
 TLR, Toll-like receptor; MLR, mixed
leukocyte reaction; 
 
 
 
GalCer, 
 
 
 
-galactosylceramide.T
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with hypotonic medium for 2 min to induce apoptosis, followed
by washing with cold PBS (42). After injection of OVA in either
soluble or cell-associated forms, the following tests for antigen
presentation were done. (a) CD11c
 
 
 
 DC-enriched and CD11c
 
 
 
DC-depleted spleen cells were isolated 4 h after OVA injection
and used to stimulate proliferation of OT-I or OT-II T cells in
culture as described (42). (b) 7 d after OVA injection, mice were
tested for T cell priming by quantifying OVA-specific, IFN-
 
 
 
and IL-4 producing T cells in the spleen as described above. (c)
Mice were given 10
 
6
 
 OT-I OVA-specific T cells i.v. and 1 d later
the animals were primed with OVA and 
 
 
 
GalCer; 3 d later, the
OVA-specific T cells were monitored for expansion in cell num-
bers and intracellular IFN-
 
 
 
 production (22). (d) CD11c
 
 
 
 DC-
enriched and CD11c
 
 
 
 DC-depleted spleen cells were isolated 4 h
after OVA injection and used at a dose of 1 and 10 
 
 
 
 10
 
6
 
 respec-
tively to prime naive recipients, assessed as in approach (b) above.
 
Tumor Protection Experiments.
 
2 
 
 
 
 10
 
7
 
 OVA pulsed apoptotic
spleen cells were used to immunize mice, either mice given OT-I
OVA-specific T cells i.v. 1 d earlier or naive animals, (42). 3 d
later, 2 
 
 
 
 10
 
6
 
 EG7, OVA-transduced tumor cells (American
Type Culture Collection; CRL-2113) were inoculated s.c. The
parental non-OVA transduced EL-4 thymoma was used as con-
trol tumor. To identify protective cells, we used blocking anti-
bodies given i.p. 2 d before tumor inoculation and every 2 d af-
ter. The antibodies were control rat IgG, rat anti-CD4 (GK1.5)
and CD8 (53–6.72), and rabbit anti-asialoGM1 Ab or control
rabbit IgG in PBS. Mice were killed when tumor growth ex-
ceeded 400 mm
 
2
 
.
 
Statistical Analysis.
 
The statistical significance of differences
between the experimental groups was determined by the Mann-
Whitney exact rank sum test.
 
Results
 
Maturation of the DC Surface After a Single I.V. Injection of
 
 
 
GalCer.  GalCer enhances resistance to tumors and in-
fections and is also presented by DCs to NKT cells (Intro-
duction). We used several criteria to test if  GalCer leads
to in vivo maturation of DCs, including their capacity to
simultaneously capture and present antigen to diverse
TCR   T cells and induce immunity. After i.v. adminis-
tration of  GalCer, both CD8  and CD8  DC subsets
up-regulated several markers consistent with maturation.
This included molecules involved in T cell costimulation
(CD40, 80, 86), as well as antigen capture and presenta-
tion (MHC class II and the DEC-205 endocytic receptor;
Fig. 1 A, compare the tracings for  GalCer with the black
tracing for the vehicle control). These responses to gly-
colipid paralleled those seen with other known stimuli for
DC maturation in vivo (Fig. 1 A), i.e., LPS (15), CpG
deoxyoligonucleotides (16, 17), and agonistic anti-CD40
mAb (20–22).
When the kinetics of the splenic DC response to  Gal-
Cer was examined, as shown for CD86, maturation was
evident within 4 h, and then began to subside at 48 h, re-
turning to baseline at 72 h (Fig. 1, B and C). Axillary
lymph node DCs from the same mice only showed mini-
mal increases in CD86 and CD40 (Fig. 1 D). The kinetics
of the splenic DC response to  GalCer was similar to that
seen with LPS treatment (unpublished data). However,
 GalCer was unable to directly stimulate DC maturation
from bone marrow progenitors in culture, in contrast to
LPS (Fig. 1 E). Therefore,  GalCer acts as a rapid and effi-
cient inducer of splenic DC maturation in vivo, compara-
ble in efficacy to other stimuli, but it does not have a direct
effect on DCs, unlike other maturation stimuli.
NKT Cells Mediate DC Maturation in a MyD88-indepen-
dent Manner. NKT cells respond quickly to the presenta-
tion of  GalCer on CD1d molecules (43). To address the
role of NKT cells in the rapid maturation of DCs, we
tested mice lacking these T cells because of the deletion of
essential TCR J 281 sequences (44). The DCs from
J 281 /  mice did not mature in response to  GalCer in
vivo and expressed comparable levels of CD86 and other
maturation markers (CD40, CD80, MHC II) to wild-type
mice given the PBS vehicle control (Fig. 2 A, left). As a
positive control, DCs from J 281 /  mice were shown to
mature in response to LPS and express high levels of CD86
(Fig. 2 A, right). We then tested DCs from MyD88 / 
mice, where MyD88 is an essential adaptor protein for sig-
naling cytokine production via Toll-like receptors (TLRs;
references 45 and 46). The DCs from MyD88 /  mice did
respond to  GalCer, maturing as effectively as DCs from
wild type mice (Fig. 2 B). DCs from NK cell-depleted ani-
mals (using anti-asialoGM1 antibody treatment [31]) also
matured in response to  GalCer (Fig. 2 C). Therefore,
 GalCer in concert with NKT cells rapidly matures DCs
in situ, as assessed by the surface markers of DCs in spleen,
but the response does not require MyD88-based signaling
or NK cells.
Functional Maturation of  GalCer-stimulated DCs. To
demonstrate that DCs from  GalCer treated mice could
stimulate resting T cells, we isolated DCs with anti-CD11c
magnetic beads and tested them in some standard assays for
DC maturation, e.g., as stimulators for allogeneic T cells in
the primary mixed leukocyte reaction (MLR). DCs from
all groups of mice (controls and mice treated with  GalCer
or LPS) stimulated allogeneic T cell proliferation (Fig. 3 A)
and to a much lesser extent, syngeneic T cell proliferation
(Fig. 3 B). As splenic DCs are able to mature “spontane-
ously” in culture (47), we also tested DCs that were fixed
in paraformaldehyde immediately upon isolation, to assess
their MLR stimulating activity at the time of isolation. The
fixed DCs from control mice no longer had stimulating ac-
tivity for the MLR (Fig. 3 C), confirming prior work that
most DCs in a spleen are functionally immature (20–22). In
contrast, fixed DCs from  GalCer treated mice were po-
tent stimulators of the allogeneic MLR (Fig. 3 C), suggest-
ing the DCs had matured in the mice before isolation and
fixation. With both live and fixed cells, CD11c  spleen
cells lacked MLR stimulating activity at the doses tested
(Fig. 3, A–D, open symbols). To prove that enhanced
MLR stimulation by CD11c  DCs was dependent upon
NKT cells, we repeated the experiments on fixed DCs
with J 281 /  mice. The increase in MLR stimulation was
now ablated (Fig. 3 E).
Maturation stimuli also can prime DCs in vivo to pro-
duce large amounts of immune enhancing cytokines suchT
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as IL-12 (48), IFN-  (49), and IFN-  (50). We studied
cytokine production by cells from mice stimulated 8 h in
vivo with  GalCer i.v., with LPS in comparison. We pre-
pared CD11c  DC-enriched and CD11c  DC-depleted
cells, and further fractionated the DCs into CD8  and
CD8  subsets. The CD11c  DCs contained few contami-
nating T and NK cells (0.5% CD3  and  0.1% NK1.1 ;
unpublished data), while the DC subsets (CD8  and
CD8 ) were obtained after depletion of T cells with anti-
CD5 (Materials and Methods). CD11c  DCs from  Gal-
Cer treated mice produced very high levels of IFN-  (Fig.
3 F). As prior work (48) showed that IL-12 production by
DCs requires sequential stimuli from a microbe and then a
T cell, e.g., through CD40 stimulation, we restimulated
the DCs primed to  GalCer in vivo with anti-CD40 in
culture. Now the DCs from  GalCer primed mice also
produced IL-12 p70, in contrast to DCs from either PBS
or LPS treated mice (Fig. 3, F and G). DCs from PBS,
LPS, and  GalCer treated mice all produced IL-12 p40,
possibly because of stimuli arising during their isolation
and culture, but as in the case of IFN- , production of IL-
12 p40 and p70 were most active in the CD8  DC subset
Figure 1. Maturation of DC
surface markers with  GalCer
and other stimuli in vivo. (A) 24 h
after i.v. administration of LPS
(25  g), CpG ODN (10  g), ag-
onistic anti-CD40 mAb (50  g),
 GalCer (2  g), or PBS (black
tracing) to C57BL/6 mice, low
density spleen cells were stained
with PE-CD11c and FITC-
CD8  (to identify DCs and their
CD8  or CD8  subsets) and
with biotinylated isotype con-
trol, anti-CD40, CD80, CD86,
I-Ab, and DEC205/CD205 fol-
lowed by streptavidin APC. (B
and C) As in (A), but the surface
markers of CD8  or CD8  DCs
were followed at the indicated
time points after i.v. administra-
tion of the maturation stimulus;
data shown are for CD86 expres-
sion. (D) Minimal up-regulation
of CD40 and CD86 on lymph
node DCs (relative to splenic
DCs) 24 h after  -GalCer i.v.
Dotted line is the isotype con-
trol, gray shadow is antigen ex-
pression at time 0, and bold
black line is CD40 and CD86
stain at 24 h. (E) Inability of
 GalCer to induce the matura-
tion of DCs from bone marrow
progenitors, in contrast to LPS,
as shown for up-regulation of
CD86 on CD11c  DCs from
day 6–7 in culture.T
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(Fig. 3, F and H). In contrast to these findings with DC
stimulated in vivo with  GalCer, Ohteki et al. showed
that the CD8  DC subset from Listeria-infected mice was
more active in IFN-  production after stimulation with
IL-12 in vitro (49). We could not detect IL-4 and IL-10
( 10 pg/ml) in DCs from  GalCer primed mice (unpub-
lished data). Interestingly, DCs stimulated by LPS in vivo
responded to CD40 restimulation in culture by producing
IL-18 rather than IL-12 (unpublished data). In sum,  Gal-
Cer matures DCs to produce enhancing cytokines and to
more actively stimulate quiescent T cells in the mixed
leukocyte reaction.
DCs Responding to OVA plus  GalCer Prime CD4  and
CD8  T Cells in Culture. To prove that DC maturation
was associated with enhanced immunogenicity, we next
injected mice with the protein antigen, OVA, either as a
soluble protein or in association with dying TAP /  sple-
nocytes (the TAP /  deletion ensured OVA presentation
by MHC class I of recipient DCs rather than the injected
splenocytes [21]), without or with  GalCer. Then we iso-
lated the DCs and non-DC fractions from spleen and mea-
sured their capacity in tissue culture to stimulate CD8 
and CD4 , OVA-specific, naive OT-I and OT-II, TCR
transgenic T cells respectively (Fig. 4 A). With both solu-
ble (Fig. 4 B) and cell-associated OVA (Fig. 4 C) as anti-
gen, the DCs selectively and actively stimulated prolifera-
tive responses by the naive CD4  and CD8  T cells in
culture; CD11c  cells were inactive (Fig. 4, B and C). The
T cells produced substantial IFN- ,  10 ng/ml culture,
but no detectable IL-4 (unpublished data), indicating that
antigen-capturing DCs were able to polarize the Th1 type
of T cell differentiation.
The apparent lack of T cell stimulating activity in the
CD11c  fractions was puzzling, because these cells should
include marginal zone B cells that express high levels of
CD1d (51, 52) and are activated by  GalCer in vivo (53).
Therefore, in the OVA experiments of Fig. 4, we also en-
riched CD19  CD21  CD23  marginal zone B cells and
Figure 2. DC maturation by  GalCer in vivo requires NKT cells. (A) Maturation, assessed by increased CD86 expression, did not occur in J 281 / 
mice (lacking NKT cells) exposed to  GalCer (left), but did occur with LPS (right). (B) Maturation of DCs from MyD88  /  mice in response to
 GalCer and LPS, and (C) from mice depleted of NK cells by anti-asialoGM1.T
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CD19  CD21  CD23  follicular B cells. We confirmed
that the former had higher levels of CD1d and that both
types of B cell up-regulated CD86 in response to  GalCer
(Fig. 4 D, left part of figure). Both B cell types failed to
present OVA (Fig. 4 D, right part of figure), especially
when compared with the CD11c  DCs isolated from these
same animals (Fig. 4 B). Thus, DCs are the major cell type
that acquires stimulating activity for naive T cells in re-
sponse to the combined administration of a foreign protein
and  GalCer.
OVA Together with  GalCer as Adjuvant Primes CD8  T
Cells In Vivo and Increases Resistance to OVA-expressing Tu-
mors. To monitor the activation of OVA-specific CD8 
T cells more directly in vivo, mice were injected i.v. with
106 CFSE-labeled CD8 , OVA-specific, TCR transgenic
T cells. 1 d later, OVA-loaded splenocytes were given
without or with  GalCer. 3 d after injection of the OVA-
loaded splenocytes, there was extensive expansion of the
injected OT-I T cells and dilution of the CFSE label (pro-
liferation). The injection of  GalCer together with antigen
increased the frequency of cells in the spleen by threefold
(Fig. 5 B) and induced them to express high levels of the
activation antigen CD44 (unpublished data). The spleen
cells were also cultured with or without OVA peptide to
determine if the T cells, gated for expression of the V 2
OT-I TCR, had been primed to produce IFN- . The use
of the  GalCer adjuvant induced high level IFN-  pro-
duction in most OT-I T cells (Fig. 5 B), but no detectable
IL-4 (unpublished data). To verify that  GalCer-depen-
dent priming was associated with enhanced resistance to
OVA-expressing tumors, we gave mice 106 OT-I T cells
i.v. and 1 d later, we administered  GalCer and OVA-
loaded cells also i.v. 3 d later, we injected 2   106 EG7
cells into the skin, where EG7 is a murine thymoma trans-
duced to express OVA in a secretory form. The mice
primed with TAP /  / OVA and  GalCer showed strong
resistance to the tumor, whereas mice primed with TAP / /
OVA splenocytes alone showed some resistance, but the
EG7 tumors recurred (Fig. 5 C). We repeated the experi-
ments in mice depleted of CD8  or CD4  T cells with
monoclonal antibodies, or NK cells with anti-asialo GM1
(these depletions were begun 1 d after administering  Gal-
Figure 3. Functional matura-
tion of splenic DCs from  GalCer
treated mice. 8 h after i.v. ad-
ministration of  GalCer, LPS or
PBS, as in Fig. 1, spleen DCs
were isolated using anti-CD11c–
coated magnetic beads (purity
 95   2%). Graded numbers of
spleen DCs from C57BL/6 mice
were irradiated (30 Gy) and
added to 2   105 allogeneic
BALB/c (A) or syngeneic (B) T
cells for 3 d in flat bottomed 96-
well plates. In parallel, DCs were
fixed with paraformaldehyde for
30 min, to block their matura-
tion during the mixed leukocyte
reaction, and also irradiated, fol-
lowed by addition to allogeneic
(C) and syngeneic (D) T cells.
Proliferative responses were
measured by [3H]-thymidine
incorporation (Materials and
Methods). The results are repre-
sentative of four independent
experiments. In E, the experi-
ment in B was repeated compar-
ing fixed DCs from wild-type
and J 281 /  NKT deficient
mice given  GalCer or vehicle.
The results are averages of three
independent experiments. (F and
G) Mice were given PBS,
 GalCer, or LPS i.v. and 8 h
later, CD11c  DC enriched and
CD11c  DC-depleted, low den-
sity spleen cells were isolated
with  -CD11c coated magnetic beads. In parallel, to test cytokine production by DC subsets, the low density spleen cells were first lymphocyte depleted
with CD5  and CD19  magnetic beads, and then CD8  and CD11c  cells were selected successively with magnetic beads, providing enriched CD8 
and CD8  DC subsets respectively. IFN-  secretion (pg/ml) by each cell subset was measured by ELISA assays after culturing the cells for 48 h without
further stimulation in 96 well plates at 2   105/well (F), while IL-12 production was measured in cells cultured 72 h in the presence of 10  g/ml agonis-
tic FGK45.5 anti-CD40 antibody at 3   105/well (G and H). All results required pools of three mice and represent averages of three independent exper-
iments (*P   0.05).T
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Cer to allow time for the NKT cells, which express CD4,
to mature the DCs). Only CD8 depletion ablated the resis-
tance induced by OVA-loaded splenocytes together with
 GalCer (Fig. 5 D).
To determine if  GalCer could serve as an adjuvant for
generating specific CD4  or CD8  T cell responses to
OVA in naive animals, we injected 2   107 dying cells
loaded with OVA i.v., and half the animals also received
Figure 4. DCs capturing OVA protein and matured by  GalCer in vivo efficiently stimulate naive CD4  and CD8  T cells in culture. (A) Schematics
for the experiments in Figs. 4, 6, and 7. Mice were given  GalCer or vehicle (PBS) together with OVA protein (5 mg/mouse) i.v. or osmotically
shocked syngeneic splenocytes loaded with OVA protein as described (reference 21). 4 h later, CD11c  cells or CD11c  cells were isolated and tested for
their capacity to stimulate CD8  and CD4  TCR transgenic T cells from OT-I and OT-II mice, respectively. T cell proliferation was measured after
[3H]-thymidine at 36–48 h. In some experiments (Fig. 5), OVA-specific T cell responses in spleen were evaluated 1 wk after immunization, while in oth-
ers (Fig. 7), CD11c  cells were transferred into naive mice to prime T cells in vivo. (B and C) The responses of CD4  (OT-II) and CD8  (OT-I) T cells
to CD11c  (top) and CD11c  (bottom) spleen cells from mice given soluble OVA (left panels) or cell-associated OVA (right panels) in the absence or
presence of  GalCer; representative of three independent experiments. (D) As in B, but enriched populations of CD21high marginal zone B cells and
CD21low follicular B cells were isolated by cell sorting and studied for CD1d and CD86 expression, as well as presentation of the injected soluble OVA to
OT-I T cells. CD21high marginal zone B cells are the upper group of data on the right, while CD21low follicular B cells are the lower group (note much
lower values on y-axis for D vs. B and C).T
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 GalCer. 7 d later, we tested if splenic T cells would se-
crete IFN-  in response to rechallenge with OVA pep-
tides presented on MHC class I or II products (Fig. 4 A for
diagram of protocol).  GalCer did serve as an adjuvant to
prime CD4  and CD8  T cells in vivo, as illustrated by
intracellular cytokine staining for IFN-  in Fig. 6 A and
summarized in Fig. 6 B. IL-4 production was not detect-
able (unpublished data). When we tried to prime J 281 / 
mice lacking NKT cells; however,  GalCer no longer
served as an adjuvant (Fig. 6 B, bottom). To establish that
the observed T cell immunity in wild-type mice was asso-
ciated with protective resistance, we verified that naive
mice immunized with the combination of TAP / /OVA
splenocytes and  GalCer showed resistance to OVA-
transduced EG7 tumor cells, but no resistance to the par-
ent EL-4 thymoma that was not transduced to express
OVA (Fig. 6 C, compare left and right panels). In sum-
mary, a single intravenous dose of  GalCer acts as an adju-
Figure 5.  GalCer enhances
immunity to OVA-bearing DCs
in vivo. (A and B) 1 d after trans-
ferring 106 CFSE-labeled OT-I
cells i.v. into C57BL/6 mice,
four groups of mice were given
either no treatment, osmotically
shocked and OVA loaded
TAP /  spleen cells,  GalCer
(2   g/mouse), or both OVA
loaded spleen cells and  GalCer.
3 d later, spleen cells were moni-
tored for dilution of fluorescence
in the CFSE labeled V 2  OT-I
cells in the spleen. IFN-  pro-
duction was monitored in tan-
dem after culturing the spleen
cells without or with OVA257–264
(1  M) for 6 h in the presence of
GolgiPlug. Each panel shows the
percentage of cytokine produc-
ing, CFSE-labeled, V 2  cells in
the spleen. (C and D) At day 3
after immunization as in A and
B, the mice were injected s.c.
with EG7 tumor cells, which
stably express OVA as a secreted
protein. Mean tumor sizes at 2 d
intervals were plotted on the left,
and the distribution of tumor
sizes at day 18 in the individual
animals shown on the right. The
experiments in the bottom pan-
els were similar to those in the
top except that mice were im-
munized with OVA loaded
spleen cells and  GalCer but de-
pleted of individual lymphocyte
subsets (from 2 d before tumor
inoculation to the end of the ex-
periments) with monoclonal an-
tibodies as indicated.T
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vant for combined Th1 type CD4  and CD8  T cell im-
munity in mice.
The Adjuvant Action of  GalCer Is Due to Mature DCs.
Given the evidence for T cell responses to the coadminis-
tration of protein antigen and  GalCer, we wanted to
prove that the mature DCs were responsible for the gly-
colipid’s adjuvant action. To do so, we again gave mice
OVA antigen as a soluble protein or in association with
dying cells. Then we isolated CD11c  DCs from spleen
4 h later and tested their capacity to generate CD4  and
CD8  effector T cells in naive animals (Fig. 4 A for dia-
gram of the protocol). We monitored T cell priming by
looking at day 7 for IFN-  production by both T cell sub-
sets using an intracellular cytokine secretion assay per-
formed on lymph node and spleen cells cultured for 6 h
with or without OVA peptides in the presence of brefeldin
A (Materials and Methods).
We first obtained DCs from 4 groups of mice primed
with vehicle, OVA only,  GalCer only, or both OVA and
 GalCer. The latter DCs primed IFN-  producing CD4 
and CD8  T cells in naive mice (Fig. 7, A and B; top pan-
els). The results were virtually identical in spleen (Fig. 7)
and lymph node (unpublished data). Again, no IL-4 pro-
ducing T cells could be detected (unpublished data). We
were concerned that some of the primed IFN-  producing
cells might be NKT cells, but very few of the CD4  and
CD8  cytokine producers labeled for the NK1.1 marker
(unpublished data), presumably because at day 6, the NKT
response to  GalCer on DCs has largely subsided (31).
It remained possible that the transferred mature DCs in
Fig. 7 were not priming naive T cells directly, but still re-
quired either NK or NKT cells in the recipient animals.
We therefore repeated the experiments but injected the
DCs (from mice primed with OVA splenocytes and  Gal-
Cer) into three groups of recipients: control mice treated
with rabbit Ig, mice treated with rabbit anti-asialoGM1 to
deplete NK cells (31), and mice depleted of NKT cells
through deletion of the J  281 genetic sequences (44). In
Figure 6. Induction of strong
immunity in naive mice with
cell associated OVA together
with   GalCer. (A) Priming of
naive mice with the combination
of 2   107 OVA-loaded, TAP / 
spleen cells and  GalCer (2  g/
mouse) i.v. 7 d later, spleen cells
were cultured without or with
OVA257–264 or OVA323–339 pep-
tides to stimulate OVA specific
CD8  and CD4  T cells respec-
tively and T cell production of
IFN-  was measured by intracel-
lular cytokine staining (the fre-
quency of T cells producing IL-4
was  0.04% for all groups). (B)
Same as (A), but means are
shown for four individual mice
(*P   0.05, **P   0.01 for the
wild-type mice primed with
OVA-loaded, TAP /  spleen
cells and  GalCer vs. the other
groups). CD4  and CD8  T cell
responses were elicited by
OVA323–339 and OVA257–264 pep-
tides respectively. (C) 1 wk after
immunization in each group,
mice were challenged with ei-
ther 2   106 EG7 or EL-4 tumor
cells. The data are mean tumor
sizes   SEM of 6 (EG7) or 3–4
(EL4) individual mice in inde-
pendent experiments. (TAP / /
OVA    GalCer vs. the other
groups at day 18; P   0.005).T
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all cases, the DCs from mice given OVA together with
 GalCer were able to prime the recipients (Fig. 7, A and
B; lower rows). Therefore the NKT cell dependent matu-
ration of antigen capturing DCs by  GalCer in donor mice
leads to the priming of Th1 CD4  and CD8  effector T
cells in naive recipient animals.
Discussion
Stimuli for the Maturation of DCs In Situ. Most DCs in a
mouse spleen are functionally immature in the steady-state,
but they undergo rapid maturation in response to  GalCer.
Several criteria have been used here to document the full
maturation of DCs, which in prior studies has been moni-
tored primarily at the level of increased expression of co-
stimulatory molecules like CD86. Here we have emphasized
the capacity of DCs in vivo to become potent stimulators of
immunity, the classical criterion for maturation.
A useful functional marker for maturation is enhanced T
cell stimulatory activity in the mixed leukocyte reaction. It
seems that this is best assayed with chemically fixed DCs, as
fixation should prevent DCs from undergoing “spontane-
ous” maturation in culture (47). When this is done, DCs
from control mice are weak MLR stimulators, whereas
formaldehyde-fixed DCs from  GalCer treated mice are
potent. This maturation criterion is fully dependent upon
NKT cells. It has also been reported that some features of
DC maturation are induced by CD1d-restricted human
NKT cell clones in vitro (54).
Maturation of DCs in mice also has been achieved by
stimuli for toll like receptors, e.g., LPS (15) and CpG oli-
godeoxynucleotides (16, 17). Likewise TCR   T cells in-
Figure 7. DCs isolated from
mice given OVA together with
 GalCer are able to prime naive
animals. Mice were given  Gal-
Cer or vehicle together with ei-
ther OVA protein (5 mg/mouse)
i.v. (A) or with osmotically
shocked TAP /  splenocytes
without or with OVA loading
(B). 4 h after injection, 106
CD11c  DCs from each group
were transferred to naive synge-
neic mice. In the top panels, 7 d
after immunization with DCs
but no further antigen or  Gal-
Cer, spleen cells were cultured
without (open bars) or with
(closed bars) OVA peptides with
GolgiPlug to allow accumulation
of intracellular IFN-  as described
in experimental procedures. In-
tracellular IFN-  staining was
performed with double labeling
for CD4 and CD8. In the bottom
panels, the DCs were taken from
mice given  GalCer together
with either OVA protein (A) or
OVA loaded splenocytes (B), but
the DCs were injected into ei-
ther rabbit Ig (control)-treated
mice or mice lacking NKT and
NK cells (see Results) to test
priming of CD4  and CD8 ,
IFN-  producing effector T
cells. The data are mean   SEM
of three individual mice in inde-
pendent experiments. *P   0.05.T
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duce DC maturation in vivo, as assessed by the up-regula-
tion of surface costimulatory molecules (18, 19). In this
paper,  GalCer harnesses NKT cells to fully mature DCs as
evidenced by the induction of immunity to antigens coad-
ministered with the glycolipid. In contrast to T cell–medi-
ated maturation, which is a part of an adaptive immune re-
sponse, NKT cells are innate cells that mature most of the
DCs in spleen very quickly, within 4 h of administering
 GalCer by the intravenous route.
Mechanisms of Maturation via  GalCer. The maturation
of DCs after presentation of  GalCer to NKT cells seems
to operate independently of TLR signaling. MyD88 is one
of the adaptor proteins for signaling cytokine production
through TLRs, but MyD88 is not required for the matura-
tion of DCs by  GalCer. DCs have a MyD88-indepen-
dent but TLR-dependent maturation pathway, especially
through TLR4 (55, 56). However, this should lead to Th2
type responses (57), whereas DCs matured from  GalCer
treated, MyD88 knockout mice induce Th1 type responses
(unpublished data).
Transactivation of NK and B cells following administra-
tion of  GalCer is well known (58). As a high proportion
of many cell types including DCs are activated in response
to the glycolipid, a “cytokine storm” induced by  GalCer
likely is playing a role. However, it is requiring a good deal
of experimentation to identify the mechanisms of NKT-
dependent DC maturation in vivo, and this will be the sub-
ject of a future report.
 GalCer as an Adjuvant for Th1 Type Cell-mediated Immu-
nity. It may be surprising that  GalCer matures splenic
DCs and also acts as an adjuvant for strong Th1 type CD4 
and CD8  T cell responses to antigens given i.v., as nu-
merous reports have used this same compound to suppress
experimental, Th1-dependent autoimmune diseases (33–
38, 59). Naumov et al. have reported that  GalCer treat-
ment of autoimmune prone animals induces a form of
tolerogenic DCs in the lymph nodes that drain the target
organ for the autoimmune disease (37). The basis for these
ostensibly major differences in immunologic outcome is
unclear, i.e., polarization in our study to Th1 responses
versus polarization toward Th2 in other studies. However,
the experimental designs are different. We have used a sin-
gle intravenous dose of glycolipid to activate DCs to pro-
duce Th1 polarizing cytokines such as IFN-  and IL-12 at
the same time that antigens are given i.v. for presentation
by the maturing DCs. In contrast, repeated doses of  Gal-
Cer have been given to treat autoimmune prone mice. In
other instances, a multiple dose regimen (60) or the s.c. ad-
ministration of OVA together with CFA (61), have been
associated with Th2 polarization to external antigens in re-
sponse to  GalCer. A Th2 environment may originate
from the finding that soluble  GalCer is able to anergize
NKT cells after the initial cytokine response, such that the
NKT cells can no longer respond to DCs and in particular
to produce IFN-  (31).
To document the role of DC maturation for adjuvant
function in vivo, we have isolated the CD11  DC-
enriched and CD11c  DC-depleted populations from the
spleens after injection of either soluble or cell-associated
OVA antigen in the absence or presence of  GalCer.
Strong CD4  and CD8  T cell responses are induced by
DCs from  GalCer-treated mice, whereas we do not de-
tect immunogenicity with non-DCs from these animals.
This adoptive transfer approach therefore establishes that
mature DCs are responsible for the in vivo action of adju-
vants, since the recipients of the DCs do not require addi-
tional exposure to OVA antigen,  GalCer adjuvant, or in-
nate NKT and NK cells. In the case of cell-associated
OVA, this antigen is known to induce peripheral tolerance
in the absence of  GalCer (21), so that the protective tu-
mor immunity we have observed overrides an otherwise
tolerogenic situation. These data indicate that DCs are nec-
essary and sufficient for the adjuvant role of  GalCer, in-
cluding its capacity to enhance CD8  T cell responses to
nonreplicating forms of a protein antigen. To harness the
adjuvant properties of this glycolipid, however, DCs need
to capture the antigen or vaccine in question and also
present the  GalCer to NKT cells.
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